Friday, June 19, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 908 of 1,261

  1. US 8258148

    Spiroindoline modulators of muscarinic receptors

    Vertex Pharmaceuticals Incorporated · Granted Sep 4, 2012 · Expires Aug 30, 2032

    granted

  2. US 8258142

    Substituted 8-[6-amino-3-pyridyl]xanthines

    Dogwood Pharmaceuticals, Inc. · Granted Sep 4, 2012 · Expires Aug 30, 2032

    granted

  3. US 8258122

    3-([1,2,4]triazolo[4,3-a]pyridin-7-yl)benzamide derivatives

    Almirall, S.A. · Granted Sep 4, 2012 · Expires Aug 30, 2032

    granted

  4. US 8258116

    Combination therapy for the treatment of HCV infection

    Vertex Pharmaceuticals Incorporated · Granted Sep 4, 2012 · Expires Aug 30, 2032

    granted

  5. US 8257918

    Intelligent nanomedicine integrating diagnosis and therapy

    The Regents of the University of California · Granted Sep 4, 2012 · Expires Aug 30, 2032

    granted

  6. US 8258106

    Immunostimulatory nucleic acid molecules

    The United States of America, as represented by the Department of Health and Human Services · Granted Sep 4, 2012 · Expires Aug 30, 2032

    granted

  7. US 8257719

    Oral care layer and related method of manufacture

    Ranir, LLC · Granted Sep 4, 2012 · Expires Aug 30, 2032

    granted

  8. EP 2491925

    Antitumorigene Kombinaton, die Cabazitaxel und Cisplatin umfasst

    AVENTIS PHARMA SA [FR] · Granted Aug 29, 2012 · Expires Aug 24, 2032

    granted

  9. US 8252541

    Sodium channel protein type III α-subunit splice variant

    Vertex Pharmaceuticals Incorporated · Granted Aug 28, 2012 · Expires Aug 23, 2032

    granted

  10. US 8252836

    Preparations of phospholipids and pharmaceuticals containing 5-amino salicylic acid for the treatment of inflammatory bowel disease

    The Board of Regents of the University of Texas System · Granted Aug 28, 2012 · Expires Aug 23, 2032

    granted

  11. US 8252923

    Peptidomimetic protease inhibitors

    Vertex Pharmaceuticals Incorporated · Granted Aug 28, 2012 · Expires Aug 23, 2032

    granted

  12. US 8252267

    DKKL-1 splice product modulators for cancer diagnosis and therapy

    Sagres Discovery, Inc. · Granted Aug 28, 2012 · Expires Aug 23, 2032

    granted

  13. US 8252937

    1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones

    Addex Pharma, S.A. · Granted Aug 28, 2012 · Expires Aug 23, 2032

    granted

  14. US 8252291

    Bacteriocins and novel bacterial strains

    The United States of America, as represented by the Secretary of Agriculture · Granted Aug 28, 2012 · Expires Aug 23, 2032

    granted

  15. US 8252538

    MicroRNA expression signature for predicting survival and metastases in hepatocellular carcinoma

    The United States of America as Represented by The Secretary of the Department of Health and Human Services National Institutes of Health Office of Technology Transfer · Granted Aug 28, 2012 · Expires Aug 23, 2032

    granted

  16. US 8252338

    Synthetic LDL as targeted drug delivery vehicle

    The Regents of the University of California · Granted Aug 28, 2012 · Expires Aug 23, 2032

    granted

  17. US 8252545

    Peptides of a melanoma antigen and their use in diagnostic, prophylactic, and therapeutic methods

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Aug 28, 2012 · Expires Aug 23, 2032

    granted

  18. US 8252737

    Antimicrobial peptides and methods of use

    The Regents of the University of Colorado · Granted Aug 28, 2012 · Expires Aug 23, 2032

    granted

  19. US 8252574

    Pseudoinfectious flavivirus and uses thereof

    The Board of Regents of the University of Texas System · Granted Aug 28, 2012 · Expires Aug 23, 2032

    granted

  20. US 8252550

    Targeting poly-γ-glutamic acid to treat Staphylococcus epidermidis and related infections

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Aug 28, 2012 · Expires Aug 23, 2032

    granted

  21. US 8252791

    Purine compounds as cannabinoid receptor blockers

    Jenrin Discovery, LLC · Granted Aug 28, 2012 · Expires Aug 23, 2032

    granted

  22. US 8252578

    Juvenile hemochromatosis gene (HFE2A) cleavage products and uses thereof

    Xenon Pharmaceuticals Inc. · Granted Aug 28, 2012 · Expires Aug 23, 2032

    granted

  23. US 8252764

    Compositions and methods of use of targeting peptides against placenta and adipose tissues

    The Board of Regents of the University of Texas System · Granted Aug 28, 2012 · Expires Aug 23, 2032

    granted

  24. US 8252767

    Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists

    Dogwood Pharmaceuticals, Inc. · Granted Aug 28, 2012 · Expires Aug 23, 2032

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.